Wells Fargo raised the firm’s price target on Pfizer (PFE) to $28 from $27 and keeps an Equal Weight rating on the shares. With better-than-expected EPS guidance largely driven by expense management and better COVID outlook, the firm still thinks Pfizer has a topline problem as it enters an loss of exclusivity period through the end of the decade.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PFE:
- Pfizer’s 2025 guidance positions company for EPS expansion, says BMO
- Barclays fact-checked Trump comments on pharmacy benefit managers
- Pfizer provides FY25 outlook, McCormick in talks for Sauer Brands: Morning Buzz
- Pfizer (NYSE:PFE) Surges as FY25 Forecast Aligns with Wall Street
- Early notable gainers among liquid option names on December 17th